Hepcidin agonists as therapeutic tools
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
Self-citationNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650
Self-citationHepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319
Self-citationGanz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Self-citationNicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., & Vaulont, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215686 · Cited by 1,214
Identification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127
Self-citationPapanikolaou, G., & Pantopoulos, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.06.021 · Cited by 1,070
Iron homeostasis in host defence and inflammation
Ganz, T., & Nemeth, E. (2015) · Nature Reviews Immunology · doi:10.1038/nri3863 · Cited by 843
Self-citationNon-transferrin bound iron: a key role in iron overload and iron toxicity
Brissot, P., Ropert, M., Le Lan, C., & Loréal, O. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.014 · Cited by 654
Research works printed but not linked: 19
- Oikonomidou, 2016, New strategies to target iron metabolism for the treatment of beta thalassemia, Ann N Y Acad Sci, 1368, 162, 10.1111/nyas.13018 · DOI
- Rechavi, 2008, Regulation of iron absorption in hemoglobinopathies, Curr Mol Med, 8, 646, 10.2174/156652408786241401 · DOI
- Kim, 2015, New insights into iron regulation and erythropoiesis, Curr Opin Hematol, 22, 199, 10.1097/MOH.0000000000000132 · DOI · Paper page
- Wang, 2016, Hepcidin regulation in the anemia of inflammation, Curr Opin Hematol, 23, 189, 10.1097/MOH.0000000000000236 · DOI · Paper page
- Oikonomidou, 2017, What can we learn from ineffective erythropoiesis in thalassemia?, Blood Rev, S0268-960X(17)30131-5
- Gardenghi, 2007, Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin, Blood, 109, 5027, 10.1182/blood-2006-09-048868 · DOI · Paper page
- Schrier, 2002, Pathophysiology of thalassemia, Curr Opin Hematol, 9, 123, 10.1097/00062752-200203000-00007 · DOI · Paper page
- Rivella, 2015, β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies, Haematologica, 100, 418, 10.3324/haematol.2014.114827 · DOI · Paper page
- Melchiori, 2010, beta-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload
- Schmidt, 2014, Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches, Hematol Oncol Clin North Am, 28, 387, 10.1016/j.hoc.2013.11.004 · DOI · Paper page
- Bourne, 2017, Hepcidin mimetic PTG–300 for treatment of ineffective erythropoiesis and iron overload. In: Seventh Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2017) May 7-11, 2017 [abstract], Am J Hematol, 92
- Manolova, 2017, Ferroportin inhibitors improve ineffective erythropoiesis and prevent iron loading in a beta-thalassemia disease model. In: Seventh Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2017) May 7-11, 2017 [abstract], Am J Hematol, 92
- Guo, 2013, Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice, J Clin Invest, 123, 1531, 10.1172/JCI66969 · DOI · Paper page
- Casu, 2016, Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia, Haematologica, 101, e8, 10.3324/haematol.2015.133348 · DOI · Paper page
- Pasricha, 2013, Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study, Blood, 122, 124, 10.1182/blood-2012-12-471441 · DOI · Paper page
- Silver, 2015, The hematocrit value in polycythemia vera: caveat utilitor, Leuk Lymphoma, 56, 1540, 10.3109/10428194.2014.966243 · DOI
- Breda, 2014, Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production, Hematol Oncol Clin North Am, 28, 375, 10.1016/j.hoc.2013.12.001 · DOI
- Suragani, 2014, Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia, Blood, 123, 3864, 10.1182/blood-2013-06-511238 · DOI · Paper page
- Vifor Pharma. Vifor Pharma ferroportin inhibitor enters phase-I clinical trial. http://www.viforpharma.com/en/media/press-releases/201802/2167159. Accessed 14 February 2018.
Cited by
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease
Fang, X., Ardehali, H., Min, J., & Wang, F. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00735-4 · Cited by 1,081
Iron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
Liver iron sensing and body iron homeostasis
Wang, C.-Y., & Babitt, J. L. (2019) · Blood · doi:10.1182/blood-2018-06-815894 · Cited by 360
Lactoferrin in aseptic and septic inflammation
Lepanto, M. S., Rosa, L., Paesano, R., Valenti, P., & Cutone, A. (2019) · Molecules · doi:10.3390/molecules24071323 · Cited by 147
“Among the putative innovative therapies, it has been proposed the use of Fpn agonists or hepcidin antagonists [16,74].”
BackgroundDendritic cell–derived hepcidin sequesters iron from the microbiota to promote mucosal healing
Bessman, N. J., Mathieu, J. R. R., Renassia, C., Zhou, L., Fung, T. C., Fernandez, K. C., Austin, C., Moeller, J. B., Zumerle, S., Louis, S., et al. (2020) · Science · doi:10.1126/science.aau6481 · Cited by 145
Metadata
- Authors
- Casu, C., Nemeth, E., & Rivella, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-04-19
- Volume
- 131
- Issue
- 16
- Pages
- 1790-1794
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2793944650
- Cited by
- 128
- References
- 38
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepcidin agonists as therapeutic tools. https://app.cochat.ai/papers/10.1182/blood-2017-11-737411
- The paper
- Casu, C., Nemeth, E., & Rivella, S. (2018). Hepcidin agonists as therapeutic tools. Blood. https://doi.org/10.1182/blood-2017-11-737411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.